[The effects of liraglutide on body composition and muscle strength in adult obese patients with type 2 diabetes mellitus].

Objective: The aim of the present study was to observe the effects of liralutide on body composition and muscle function in adult obese patients with type 2 diabetes. Method: A total of 63 adult obese type 2 diabetic patients who were (52.6±9.7) years of age and with body mass index (BMI) of ≥28 kg/m2 were enrolled. The patients were randomly assigned into two groups. On the basis of maintaining the original hypoglycemic regimen, patients in the control group (n=24) were given dietary guidance only, and those in the treatment group (n=39) were injected with liraglutide. All patients were followed up for a period of 12 weeks. Blood glucose, glycosylated hemoglobin(HbA1c) and insulin levels, liver and kidney function, body composition assessed with electrical impedance methods, and grip strength measured by a grip meter for muscle function were detected at the baseline and the end of the study. Results: Compared with those in the control group, the reductions in HbA1c [(-1.54±2.10) % vs.(-0.53±0.84) %], body weight [(-3.46±4.2) kg vs.(-0.34±3.66) kg], body fat mass [(-1.97±2.98) kg vs.(-0.01±2.16) kg] and visceral fat area [(-0.01±2.16) cm2 vs.(0.34±6.39) cm2] were more pronouced in liraglutide treated group (all P<0.05). However, no changes could be observed in muscle mass and grip strength after liraglutide treatment. Conclusions: In addition to reducing blood glucose, body weight and fat mass, treatment with lilaluptide had no impact on muscle mass and muscle function. Therefore, liralutide is suitable for obese patients with type 2 diabetes, especially for weight management patients who are at risk of muscle loss.目的： 观察利拉鲁肽对成年肥胖2型糖尿病患者身体成分和肌肉功能的影响。 方法： 2020年4月30日至11月30日符合入组标准的80例成年肥胖2型糖尿病患者，信封法1：1随机分为对照组和利拉鲁肽组，在原降糖方案不变的基础上，40例患者仅给予饮食指导（对照组，失访16例），40例患者使用利拉鲁肽（利拉鲁肽组，失访1例），观察12周，基线和研究终点时检测血糖、糖化血红蛋白、胰岛素抵抗指数和肝肾功能，并用电阻抗的方法进行体成分检查，用握力计检测握力评估肌肉功能。 结果： 利拉鲁肽组（39例）的糖化血红蛋白变化［（-1.54±2.10）%比（-0.53±0.84）%］、体重变化［（-3.46±4.2）kg比（-0.34±3.66）kg］、体脂肪量减少［（-1.97±2.98）kg比（-0.01±2.16）kg］和内脏脂肪面积变化［（-0.01±2.16）cm2比（0.34±6.39）cm2］明显好于对照组（24例），P值均<0.05，同时利拉鲁肽组患者治疗前后肌肉量和握力无显著改变。 结论： 利拉鲁肽除降糖外，还有减轻体重、减少脂肪并保持肌肉质量和肌肉功能的额外获益。因此利拉鲁肽适用于肥胖2型糖尿病的患者，尤其适合有肌肉量减少风险患者的体重管理。.